Arvinas Inc (ARVN)

Oct 14, 2025

Can Arvinas Inc. stock beat analyst upgradesJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com

Oct 14, 2025

Oct 14, 2025

Is Arvinas Inc. trending in predictive chart models2025 Price Momentum & AI Enhanced Trading Signals - newser.com

Oct 14, 2025

Oct 14, 2025

Can Arvinas Inc. stock withstand economic slowdownQuarterly Profit Summary & Daily Volume Surge Signals - newser.com

Oct 14, 2025

Oct 13, 2025

What data driven models say about Arvinas Inc.’s futureGap Down & Fast Entry and Exit Trade Plans - newser.com

Oct 13, 2025

Oct 13, 2025

Published on: 2025-10-13 09:51:45 - newser.com

Oct 13, 2025

Oct 13, 2025

Chart overlay techniques for tracking Arvinas Inc.July 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com

Oct 13, 2025

Oct 13, 2025

How to forecast Arvinas Inc. trends using time seriesProduct Launch & Weekly High Conviction Ideas - newser.com

Oct 13, 2025

Oct 13, 2025

Arvinas, Inc. to Present New Patient-Reported Outcomes Data for Vepdegestrant at ESMO Congress 2025 - Quiver Quantitative

Oct 13, 2025

Oct 13, 2025

Arvinas to Present Data from the Vepdegestrant Clinical - GlobeNewswire

Oct 13, 2025

Oct 13, 2025

Phase 3 PRO data lead: Arvinas' vepdegestrant to be presented at ESMO Oct 19–20, 2025 in Berlin - Stock Titan

Oct 13, 2025

Oct 10, 2025

What MACD signals say about Arvinas Inc.Earnings Miss & High Conviction Buy Zone Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reiterates Sell (E+) Rating for Arvinas (NASDAQ:ARVN) - MarketBeat

Oct 09, 2025

Oct 09, 2025

Full technical analysis of Arvinas Inc. stockTrade Risk Report & Daily Profit Maximizing Tips - newser.com

Oct 09, 2025

Oct 08, 2025

Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook By Investing.com - Investing.com South Africa

Oct 08, 2025

Oct 08, 2025

Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook - Investing.com

Oct 08, 2025

Oct 07, 2025

Arvinas Holding Company (ARVN) Receives a Hold from Bank of America Securities - The Globe and Mail

Oct 07, 2025

Oct 07, 2025

Piper Sandler raises Arvinas stock price target to $16 on LRRK2 degrader data - Investing.com

Oct 07, 2025

Oct 06, 2025

Arvinas Announces Positive Phase 1 Trial Results - TipRanks

Oct 06, 2025

Oct 06, 2025

Arvinas Says Potential Parkinson's Disease Treatment Well Tolerated in Early Trials; Shares Gain Pre-Bell - MarketScreener

Oct 06, 2025

Oct 06, 2025

Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛

Oct 06, 2025

Oct 06, 2025

Top Companies in Targeted Protein Degradation MarketBristol - openPR.com

Oct 06, 2025

Oct 06, 2025

Is Arvinas Inc. reversing from oversold territoryShort Setup & Weekly Chart Analysis and Guides - newser.com

Oct 06, 2025

Oct 05, 2025

Full Stock Market News from 2025-10-05 - Stock Titan

Oct 05, 2025

Oct 05, 2025

Arvinas (ARVN) Highlights Promising Phase 1 Trial Results for AR - GuruFocus

Oct 05, 2025

Oct 05, 2025

Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials By Investing.com - Investing.com Nigeria

Oct 05, 2025

Oct 05, 2025

Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials - Investing.com India

Oct 05, 2025

Oct 05, 2025

Arvinas, Inc. Reports Positive Phase 1 Trial Results for ARV-102 in Healthy Volunteers and Parkinson's Disease Patients - Quiver Quantitative

Oct 05, 2025

Oct 05, 2025

Arvinas Presents Late Breaking, Positive Phase 1 Clinical - GlobeNewswire

Oct 05, 2025

Oct 05, 2025

97% LRRK2 Reduction — Arvinas' ARV-102 Shows Strong PBMC Target Engagement and CSF Biomarker Modulation - Stock Titan

Oct 05, 2025

Oct 05, 2025

Will a bounce in Arvinas Inc. offer an exitJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - newser.com

Oct 05, 2025

Oct 05, 2025

Real time alert setup for Arvinas Inc. performanceJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com

Oct 05, 2025

Oct 05, 2025

Is Arvinas Inc. stock poised for growthQuarterly Market Review & Real-Time Sentiment Analysis - newser.com

Oct 05, 2025

Oct 05, 2025

Tools to monitor Arvinas Inc. recovery probabilityWeekly Loss Report & Real-Time Volume Analysis - newser.com

Oct 05, 2025

Oct 03, 2025

Can Arvinas' Brain-Penetrant PROTAC Deliver On Its Promise In Parkinson's Trials? - RTTNews

Oct 03, 2025

Oct 02, 2025

Voya Investment Management LLC Has $124,000 Holdings in Arvinas, Inc. $ARVN - Defense World

Oct 02, 2025

Oct 01, 2025

Using fundamentals and technicals on Arvinas Inc.July 2025 Outlook & Safe Capital Preservation Plans - newser.com

Oct 01, 2025

Oct 01, 2025

Arvinas, Inc. to Present Clinical Data for Investigational PROTAC LRRK2 Degrader ARV-102 at MDS 2025 Conference - Quiver Quantitative

Oct 01, 2025

Oct 01, 2025

Arvinas to Present Clinical Data for ARV-102, a PROTAC - GlobeNewswire

Oct 01, 2025

Oct 01, 2025

First-Ever PROTAC LRRK2 Degrader Human Trial Data: Arvinas Reveals Breakthrough Parkinson's Results - Stock Titan

Oct 01, 2025

Sep 30, 2025

What drives Arvinas Inc stock priceTechnical Pattern Recognition & Low Risk Investment Portfolio - earlytimes.in

Sep 30, 2025